Wednesday, 4 March 2020

Gene Expression Analysis Market Shares Analysis, Key Development Strategies and Forecasts Till 2023

Gene expression analysis is research dedicated towards functional genomics extending the application purview of studying genes and gene transcripts. Synthesizing functional gene products such as functional RNAs and protein species offers insights on how an intact organism survives when a particular gene goes missing. Growth in personalized medicine and technological developments are driving market growth. According to a data published by the Foley & Lardner LLP, Food and Drug Administration (FDA) approved 16 new personalized medicines in 2017. Moreover, the development of genomic databases and increased government funding towards genomics is fueling market growth.
However, the lack of skilled labor and the high cost of instruments may hamper market growth during the assessment period.
The Global Gene Expression Analysis Market Size is expected to grow significantly over the forecast period. It is estimated that the global gene expression analysis market is expected to hold a market value of USD 3.250 million and register a CAGR ~9.1% during the forecast period of 2018 to 2023.
Segmentation
The global gene expression analysis market has been segmented into product, services, application, end-user, and region.
The market, on the basis of product, has been segmented into consumables and instruments.
The market, based on consumables, has been further segmented into reagents and DNA chips.
The market, based on instruments, has been further segmented into polymerase chain reaction (PCR), next-generation sequencing (NGS), microarray, Sanger sequencing, and others.
The market, by services, has been segmented into gene expression profiling services, sequencing services, bioinformatics solutions, and others.
The market, by application, has been segmented into drug discovery, diagnosis, research, and others.
The market, by end-user, has been segmented into pharmaceutical & biotechnology companies, academic & research institutes, contract research organizations, and others.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The gene expression analysis market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European gene expression analysis market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
The gene expression analysis market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The gene expression analysis market in the Middle East & Africa has been segmented into the Middle East and Africa.
Key Players
Some of the key players in the global gene expression analysis market are GENERAL ELECTRIC COMPANY, Illumina, Inc., Thermo Fisher Scientific, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, Pacific Biosciences of California, Inc., BGI, PerkinElmer Inc., Agilent Technologies, Inc., QIAGEN, Oxford Gene Technology, Eurofins Scientific, Danaher, Genotypic Technology Pvt Ltd, Macrogen Inc.
Regional Market Summary
Geographically, the Americas is anticipated to dominate the global gene expression analysis market owing to the increasing research activities and the rising popularity of gene expression tests. Additionally, the well-developed healthcare sector is anticipated to boost the American gene expression analysis market.
Asia-Pacific is anticipated to be the fastest growing region in the market due to the growing investment from governments in the field of genomics, and continuously developing economies. According to a report published by the International Journal of Social and Developmental Concerns in October 2017, in Malaysia, the growth of the public primary, as well as secondary care facilities, has decreased in the past few years, and it has not kept pace with the rapid urbanization. Thus, such factors restraint the growth of the market in this region. On the other hand, the Middle East & Africa has the least share of the market.
Europe is expected to hold the second largest position in the global gene expression analysis market. The market growth in this region is attributed to the availability of funds for research.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Global Animal Genetics Market Trend, Industry Overview, Competitive Analysis and Foreseen by 2023

Market Scenario:
Animal genetics is a branch of genetics that pacts with the study of genetic variation and inheritance, primarily for domestic and wild animals. The Animal Genetics Market is expected to witness tremendous growth owing to as increased adoption of genetic services to prevent genetic diseases and business loss, and rising acceptance of advanced genetic technologies. Other key factors such significant investments in R&D and expansions undertaken by key players are contributing towards the growth of the market. However, challenges such as need for specific breeding programs for breeds with inferior economic performance, and economic sustainability in local breeds is likely to curb the market growth during the forecast period.
For the commercial level, animal genetics is used for services such as DNA typing, genetic disease testing, and genetic trait testing. This methodology uses hybrid population, ontogenetic, and cytological studies for determining the genetic hybridizations. For instance, a genetically modified cow might be able to produce more milk and can be less prone to common cattle diseases, such as clostridial disease, bovine respiratory disease complex, etc., thus, effectively increasing overall profit of the cattle farmers.
The Global Animal Genetics Market size is projected to register a CAGR of 8.4% over the forecast period.
The key factor responsible for influencing this market is increasing consumption of animal-derived protein, growing global population and rapid urbanization, and growing focus on identifying superior breeds have aided the growth of the toxicology testing market. However, factors such as, the high cost of animal testing, stringent regulatory framework for genetic engineering, and lack of skilled professionals and are expected to restrict the market growth during the forecast period.
Key players:
  • Neogen Corporation (US),
  • Genus (UK),
  • URUS (US),
  • EW Group (Germany),
  • Groupe Grimaud (France),
  • CRV Holding B.V. (The Netherland),
  • Topigs Norsvin (Netherlands),
  • Zoetis (US),
  • Envigo (US)
  • Hendrix Genetics BV (The Netherland),
  • Animal Genetics (US),
  • Alta Genetics (US),
  • vetGen (US)
Segmentation:
The Animal Genetics Market Global is segmented into animal genetic products, services, and end-user. The Animal Genetics Market, by animal genetic products, the market is segmented into genetic materials and live animals. The live animals are further bifurcated into poultry, bovine, porcine, canine and others. The genetic materials are sub-segmented into semen and embryo. On the basis of services, the animal genetics market is bifurcated into genetic disease tests, DNA typing, gene trait tests, and others. On the basis of end-user, the market is segmented into veterinary hospitals & clinics, diagnostic centers, research centers and institutes, and others
Regional Market Summary 
The Americas is the largest in the market owing to the high acceptance of animal genetics in research, the development in research expenditure along with the increasing acquisition by the market players are also accountable for the growth of the animal genetics market. For instance, in 2018, Neogen completed the acquisition of Livestock Genetic Services, a firm that specializes in genetic evaluations and data management for cattle-breeding organizations. This strategy enhances the company’s in-house genetic evaluation capabilities and further expands the company’s global network of animal genomics laboratories.
The European region is the second largest animal genetics market over the forecast period due to high consciousness about animal wellbeing coupled with increased expenditure on veterinary services in the region. As per a report by the European Pet Food Industry Federation, more than 75 million households in Europe own a pet.
The Asia Pacific region is likely to develop at the uppermost CAGR for the animal genetics market in the years to come. Moreover, the rising veterinary care services both at the veterinary hospital and at community level are expected to influence the market in a positive way.
The Middle East and Africa accounts for the least share due to low per capita income and lack of availability of well-trained healthcare professionals. However, there has been an increasing demand for test accuracy and consistency among end-users and the government in this region that is enhancing the adoption of animal genetic technology in this region.

Browse More Life Sciences Reports @ https://www.marketresearchfuture.com/categories/life-sciences-market-report
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Particle Therapy Market Key Manufactures Shares, Analysis and Forecasts Till 2023

Market Scenario:
Particle therapy is one of the world's most advanced areas of external beam radiation therapy applied to oncology. This technique saves healthier radiation tissue better than conventional photon therapy. These particles have more favorable physical intrinsic properties that reduce the intake dose to approximately 50% of the dose in a clinically relevant target.
The Global Particle Therapy Market is accounted for USD 790.45 million in 2017 and expected to register 9.1% CAGR during the forecast period (2018–2023). 
The rising prevalence of cancer population, low risk of treatment induced disorders, potential for retreatment owing to low radiation dose, and rising number of particle therapy centers across the world are expected to drive the growth of the Particle therapy market share. Moreover, rising R&D spending and aggressive strategies adopted by the top players such as new product launches are contributing to the growth of the market. For instance, in December 2017, Advanced Oncotherapy plc announced that it secures the fresh funding of USD 46.75 million from which USD 37.5 million of funds coming from a new Chinese investor. The lack of adequate reimbursement policy and high costs involved in the establishment of these centers may hamper the growth of the particle therapy market size during the assessment period.
Key Players
Some of the key players in the global particle therapy market are Advanced Oncotherapy PLC., Danfysik A/S, Hitachi, Ltd., Ion Beam Applications Sa (IBA), Mevion Medical Systems, Inc., Optivus Proton Therapy, Inc., Protom International, Inc., Provision Healthcare, LLC, Sumitomo Heavy Industries, Ltd., Varian Medical Systems, Inc.
Regional Analysis:
The market is likely to dominate by Americas during the forecast period owing to the increasing prevalence of cancer patients, rising government focused towards establishment of particle therapy centers for treatment, and well-established healthcare sector in the region. The European market is expected to be the second-largest due to government funding and support of the healthcare sector, coupled with increasing research and development. Moreover, the market in Asia-Pacific is anticipated to be the fastest-growing during the forecast period owing to technological development, increasing adoption of advance treatment from developed countries, and favorable government initiatives for healthcare facilities. The market in the Middle East & Africa is likely to account for the smallest share of the global particle therapy market.
Segmentation:
The Global Particle Therapy Market has been segmented on the basis of type, product & service, cancer type, system, and application.On the basis of type, the market has been classified as proton therapy and heavy ion therapy. The market, by product and services, has been segmented into products and services. Products are further segmented into cyclotrons, synchrotrons, and synchrocyclotrons. Based on cancer type, the market has been segmented into prostate cancer, lung cancer, pediatric cancer, head and neck cancer, breast cancer, and others. The market, by system, has been segmented into multi-room systems and single-room systems. On the basis of application, the market has been classified as treatment applications and research applications. The pediatric cancer segment is expected to hold the largest market share of the particle therapy market, by cancer type, during the forecast period. Also, research applications to register the highest CAGR in the global particle therapy market during the forecast period.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The particle therapy market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada. The European particle therapy market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The particle therapy market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The particle therapy market in the Middle East & Africa has been segmented into the Middle East and Africa. 
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Duodenal Cancer Market Opportunities, Drivers, Manufacturers, Analysis and Forecasts Till 2023

Market Scenario
Duodenal cancer, also known as the small bowel cancer, are caused in the duodenum area of the small intestine. The global duodenal cancer market is expected to grow slowly over the forecast period. It is estimated that the global duodenal cancer market is expected to register a CAGR ~ 3.2% during the forecast period of 2018–2023.
Numerous factors such as the growing prevalence of rare cancers, rising prevalence of chronic diseases, increasing, technological advancements and growing geriatric population are expected to drive the growth of the market. For instance, in January 2018, GE Healthcare announced that it has entered into a long-term, strategic partnership with Roche Diagnostics to co-develop and market digital clinical decision support solutions. With this, the companies will initially focus on products that accelerate and improve individualized treatment options for cancer and critical care patients.
Moreover, favorable healthcare expenditures boost the growth of the market. However, stringent government regulation for product approval and the high cost of the treatments may hamper the market growth during the assessment period.
Key players
AbbVie, Inc., Pfizer Inc., Eli Lilly & Company, Bristol-Myers Squibb Company, F. Hoffman-La Roche Ltd., Becton, Dickinson & Company, Novartis AG, Ipsen Biopharmaceuticals Inc., Thermo Fisher Scientific, Abbott, G E Healthcare, Agilent Technologies Inc., AstraZeneca, Boehringer Ingelheim International GmbH, and Bayer AG are some of the key players in the global duodenal cancer market.
Regional Summary
Geographically, the Americas is anticipated to dominate the global duodenal cancer market owing to a well-developed healthcare sector, rising prevalence of rare and chronic disease and growing healthcare expenditure. According to an article published by, American Society of Clinical Oncology (ASCO) in January 2018, 67% of people diagnosed with duodenal cancer survive it for five years. Europe is expected to hold the second largest position in the global duodenal cancer market. The market growth in this region is attributed to the growing prevalence of chronic diseases, availability of funds for research, and increasing healthcare expenditure. According to Cancer Research UK, 41,804 new cases of bowel cancer were reported in 2015 in the UK.
Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population, continuously developing economies, rising prevalence of diseases and increasing government funding for the healthcare sector. According to a study published by the European Society for Medical Oncology in January 2016, there were 4.3 million new cancer cases in China in 2015.
On the other hand, the Middle East & Africa has the least Duodenal Cancer Market Share. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector and growing government initiatives for the healthcare sector.
Segmentation
The global duodenal cancer market has been segmented into type, diagnosis, and treatment.
The market, on the basis of type, has been segmented into adenocarcinoma, sarcoma, neuroendocrine (carcinoid) tumors, and lymphoma.
The market, by diagnosis, has been segmented into endoscopy or colonoscopy, capsule endoscopy, barium X-ray, CT scan, MRI scan, and other tests.
The market, by treatment, has been segmented into surgery, radiotherapy, and chemotherapy.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The duodenal cancer market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European duodenal cancer market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
The duodenal cancer market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The duodenal cancer market in the Middle East & Africa has been segmented into the Middle East and Africa.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora, Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Worldwide Coronary Stent Market Top 10 Players Universal Analysis, Industry Demand and 2023 Forecast

Synopsis of the Global Coronary Stent Market
The global coronary stents market is projected to touch USD 9,382.63 million at a stupendous 7.81% CAGR over the predicted years (2018-2023). Coronary stents are utilized in angioplasty for making cross-section of blood vessels wider. The stent will reduce the chest pain along with recovering survivability during acute myocardial infarction. Coronary stents are used for treating cardiac diseases namely coronary artery disease, angina pain and myocardial infarction.
There are many factors that is driving the growth of the coronary stents market share. Some of these factors as per the Market Research Future (MRFR) report include increasing prevalence of CAD (coronary artery disease, innovations in coronary stents, increase in research and development of coronary stems, untapped emerging countries offering new market opportunities, lifestyle change diseases, increasing geriatric population, profound increase in healthcare coverage, advanced medical technologies, development of ICT (information and communication technology) and increase in government investment. On the contrary, factors such as high expenditure of procedures related to coronary stents coupled with accessibility of substitutes for CAD treatment is likely to hinder the growth of the coronary stents market.
Market Segmentation
Market Research Future report offers an all-inclusive segmental analysis of the coronary stents market on the basis of products and end user.
Based on products, it is segmented into Bioresorbable Vascular Scaffolds, Bare Metal Stents and Drug Eluting Stents. Of these, drug eluting stent is expected to lead the market during the predicted years owing to its increasing acceptance in better patient compliance, angioplasty procedures in comparison to bare metal stents. The bioresorbable stents is expected to expand at the fastest pace.
Based on end users, the coronary stents market is segmented into specialty centers, ambulatory surgical centers, hospitals and clinics and others. Of these, hospitals and clinics will have the maximum market share during the predicted years. This will be followed by the ambulatory surgical centers which will expand at the fastest rate.
Regional Analysis
Based on region, the coronary stents market covers growth opportunities and latest trends across North America, Europe, Asia Pacific and Middle East and Africa. Of these, North America will have a lion’s share in the market due to increasing cases of cardiovascular diseases mainly coronary artery disease, arterial blockage, cardiac arrythmia to name a few. Availability of advanced treatment methods and better therapeutic approaches has affected the growth of the market in this region in a positive way. The other factors that is driving the growth of the coronary stents market here include high disposable income, increasing medical awareness among the people here and existence of leading medical device manufacturers in this region. The coronary stents market in Europe holds the second largest share owing to the increasing support by the government for device manufacturers. Also, expansion of the companies geographically has resulted in a broader reach of medical services and products that has brought tremendous change with regards to acceptance as well as implementation of novel procedures and products. The coronary stents market in the APAC region experienced a huge growth due to the increasing development in the medical domain in the developing countries such as China and India. Besides, increasing medical device companies here, increasing research and development expenditure and increasing funding made by the government has resulted in its fastest growth. On the other hand, the coronary stents market in the Middle East and Africa is expected to have minimal growth opportunities.
Competitive Analysis
The coronary stents market is fragmented and highly competitive. The leading companies which have used strategies such as strategic alliances and mergers and acquisitions have gained a competitive advantage. Besides companies are highly focused to create products that are technologically advanced and deliver efficiency and greater accuracy.
Key Players
Leading players profiled in the coronary stents market include Terumo Corporation, Stentys SA, MicroPort Scientific Corporation, Meril Life Sciences, Medtronic plc, Elixir Medical Corporation, Cook Medical, R. Bard, Inc., Boston Scientific Corporation, Biotronik SE & Co. KG, and Abbott, B. Braun Melsungen AG.
Feb 2019- Biotronik has received approval from the FDA on its Ultrathin Orsiro Stent to treat coronary artery disease. This coronary stent will offer a novel treatment option to healthcare providers that will help in sealing the perforation to prevent blood leakage at the time of the procedure as well as avoid higher invasive surgical procedure or life-threatening complication.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Dry Eye Syndrome Market Key Manufactures Shares, Analysis and Forecasts Till 2023

Increasing geriatric population, rising prevalence of the diseases like diabetes, rheumatoid arthritis, growing per capita healthcare expenditure, and changing lifestyle are the major drivers for the market growth. However, factors like stringent FDA drug approvals, lack of skilled ophthalmologists, and low per capita healthcare expenditure in the middle and low income countries are estimated to restrain the market growth during the forecast period. 
The global dry eye syndrome market growth is expected to advance with an approximate CAGR of 6.6% during the forecast period.
According to the World Health Organization in 2016, approximately 422 million adults were globally affected by diabetes in 2014, as compared to 108 million in the 1980’s. Moreover, in 2014, it was estimated that the global prevalence of diabetes was estimated to be around 8.5%. Additionally, rising per capita healthcare expenditure, and changing lifestyle boosts the market. However, factors like stringent FDA drug approvals, lack of skilled ophthalmologists, and low per capita healthcare expenditure in the middle-and low-income countries are restraining the market. 
Tears provide lubrication, limits the risks of eye infections, washes away the foreign matter, thus, are helpful in keeping the surface of the eyes smooth and clear. Dry eye syndrome is a medical condition in which eyes’ lubrication is hindered by the unavailability of tears. Under normal condition, during excessive production, tears flow into the small drainage ducts of the inner corners of the eyes, followed by draining back into the nose. Sometimes when the production of tears and drainage is not balanced, it can result into dry eye syndrome. Eye redness, sensitivity to light, watery eyes, eye fatigue are some of the common symptoms of the disease. Increasing geriatric population, rising prevalence of diseases like diabetes, rheumatoid arthritis, and others are estimated to be the major drivers for the market growth.
Key Players
The key players for the global dry eye syndrome are Allergan (Republic of Ireland), Novartis AG (Switzerland), Otsuka Pharmaceutical Co. Ltd. (Japan), Valent Pharmaceuticals (Canada), Johnson & Johnson Vision (U.S.), Acadia Pharmaceutical (U.S.), Allostera Pharma (Canada), I-Med Pharma Inc. (Canada), Santen Pharmaceuticals Co. Ltd., (Japan), AFT pharmaceuticals (New Zealand), Novaliq GmBh (Germany), Auven therapeutics (U.S.), and others.
Segmentation
The global dry eye syndrome is segmented on the basis of the type, diagnosis, treatment, distribution channel and end user.
On the basis of the type, the market is segmented into evaporative dry eye syndrome aqueous dry eye syndrome, and others. On the basis of the diagnosis, the market is categorized into Schirmer test, eye exam, and others.  On the basis of the treatment, the market is segmented into nutritional supplements, serum eye drops, lubricant eye drops, anti-inflammatory drugs segments, surgery, and others. The lubricant eye drops segment is sub-segmented into oily tear eye drops, ointments, preservative-free drops, and others. The anti-inflammatory drugs segments segement is sub-segmented into tetracyclines, corticosteroids, and others. The surgery segment is sub-segmented into punctal occlusion, intense pulsed light therapy, and others. On the basis of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and others.  On the basis of the end users, the market is segmented into hospitals, clinics, home care, and others.
Regional Analysis
The Americas dominates the global dry eye syndrome market owing to the presence of a well-developed healthcare sector, huge patient population, and increasing healthcare expenditure. Moreover, the presence of the major market players like Johnson & Johnson Vision, Auven therapeutics, Acadia Pharmaceutical, and others within the region boosts the market growth. Europe stands second in the dry eye syndrome market. This is attributed to the increasing availability of funds for research, a well-developed healthcare sector, huge patient and growing geriatric population. The Asia Pacific region is estimated to be the fastest growing region for the market. Economies like India, China, Australia and others within the region have huge patient population, rising healthcare expenditure facilitating the market growth. On the other hand, the Middle East & Africa has the least share in the global dry eye syndrome. Low per capita healthcare expenditure, stringent government policies, especially within the African region restrains the market growth within the region. The Middle East holds a majority of the market due to a well-developed healthcare sector and huge healthcare expenditure.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Global Uterine Sarcoma Market Trend, Industry Overview, Competitive Analysis and Foreseen by 2023

Market Scenario:
Sarcomas are the tumours of the mesenchymal tissues like bone, muscle, connective tissue, cartilage and fat. Uterine sarcoma is a rare type of cancer which starts in the muscle and supporting tissues of the uterus. Exposure to the X-rays increases the risk for uterine sarcoma. Unusual vaginal bleeding, spotting, or discharge are some of the common symptoms for the disease. Increasing prevalence of the uterine sarcoma and growing female geriatric population are the major drivers for the market growth during the forecast period, 2017-2023. In 2017, according to the American Cancer Society, 4,910 new cases of uterine sarcomas were reported in the U.S. Moreover, according to the World Bank, the female population which aged over 65 years rose from 316.27 billion to 347.25 billion in 2016.
Additionally, rising healthcare expenditures and increasing awareness regarding women health is expected to boost the market growth. However, high cost of treatment and related side effects are the factors that can restrain the market growth. Chemotherapy is extensively exploited for the therapeutics of the uterine sarcoma. Some of the side effects of the chemotherapy are inclusive of hair loss, anemia, reduced fertility, and others.
The global uterine sarcoma market size is expected to grow at an approximate CAGR of 8.5% from 2017 to 2023.
Key players
  • Pfizer Inc.
  • Intas Pharmaceuticals Ltd.
  • FMC Corporation
  • Sun Pharmaceutical Industries Ltd.
  • Johnson & Johnson Services, Inc.
  • General Electric Company
  • Koninklijke Philips N.V.
  • Siemens Healthcare Private Limited
Segmentation
The global uterine sarcoma market is segmented on the basis of type, diagnosis, treatment, and end user.
On the basis of the treatment, the market is segmented into surgery, radiotherapy, chemotherapy, hormone therapy, and others. The surgery segment is sub-segmented into bilateral salpingo-oophorectomy, hysterectomy, and others. The chemotherapy segment is sub-segmented into dacarbazine, docetaxel, doxorubicin, and others. The hormone therapy segment is sub segmented into progestins, aromatase inhibitors, and others.
On the basis of the type, the market is segmented into uterine leiomyosarcoma (LMS), endometrial stromal sarcoma (ESS), undifferentiated sarcoma, and others.
On the basis of the diagnosis, the market is categorised into sampling & testing, imaging tests, and others. The sampling & testing segmented is sub-segmented into endometrial biopsy, dilation and curettage, cystoscopy and proctoscopy, and others. The imaging tests segment is sub segmented into transvaginal ultrasound, computed tomography, magnetic resonance imaging, positron emission tomography scan, and others.
On the basis of end users, the market is segmented into hospitals & clinics, academic institutes research organization, and others.
Regional Analysis
Asia Pacific region is also regarded to be the fastest growing market. Increasing awareness for women health and growing healthcare sector are the major drivers for the market growth within the region. Moreover, the presence of the developing countries like the India and China within the region fuels the market growth. According to the Indian Brand Equity Foundation in 2017, the Indian healthcare sector was one of the fastest growing industries in India and is expected to advance at a CAGR of 22.87% from 2015-2020.
America dominates the global uterine sarcoma market owing to increasing adoption of new technologies and huge patient population. Additionally, rising healthcare expenditure and presence of a developed healthcare sector within the region fuels the market growth.
Europe is the second largest market for uterine sarcoma owing to rising research and development in healthcare sector and huge patient population.  By region, Europe is divided into Western Europe and Eastern Europe. The presence of developed economies like France, Germany, Italy have made the Western Europe to lead the market within the region. On the other hand, Eastern Europe is the fastest growing region in Europe.
The Middle East & Africa has the least share in the global uterine sarcoma market due to presence of poor economies and stringent government policies, especially in the African region. Majority of the market of Middle & Africa region is held by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure by the presence of the economies like Saudi Arabia, Kuwait and Qatar within the region.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:
Subscribe to: Posts (Atom)